Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

OBJECTIVE: To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD). DESIGN: Retrospective case series. PARTICIPANTS AND METHODS: We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagiannis, Dimitrios A, Ladas, Ioannis D, Parikakis, Efstratios, Georgalas, Ilias, Kotsolis, Athanasios, Amariotakis, Giorgos, Soumplis, Vasileios, Mitropoulos, Panagiotis
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801585/
https://www.ncbi.nlm.nih.gov/pubmed/20054410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801585/
https://www.ncbi.nlm.nih.gov/pubmed/20054410

Ejemplares similares